Lanzavecchia A - Search Results

1

Adoptive immunotherapy of ovarian carcinoma with bs-MAb-targeted lymphocytes: a multicenter study.

Bolhuis RL, Lamers CH, Goey SH, Eggermont AM, Trimbos JB, Stoter G, Lanzavecchia A, di Re E, Miotti S, Raspagliesi F, et al. Bolhuis RL, et al. Among authors: lanzavecchia a. Int J Cancer Suppl. 1992;7:78-81. Int J Cancer Suppl. 1992. PMID: 1428412 Clinical Trial.

2

Anti-ovarian carcinoma anti-T3 heteroconjugates or hybrid antibodies induce tumor cell lysis by cytotoxic T-cells.

Canevari S, Ménard S, Mezzanzanica D, Miotti S, Pupa SM, Lanzavecchia A, Colnaghi MI. Canevari S, et al. Among authors: lanzavecchia a. Int J Cancer Suppl. 1988;2:18-21. doi: 10.1002/ijc.2910410707. Int J Cancer Suppl. 1988. PMID: 3258291

3

Janusin: new molecular design for bispecific reagents.

Traunecker A, Lanzavecchia A, Karjalainen K. Traunecker A, et al. Among authors: lanzavecchia a. Int J Cancer Suppl. 1992;7:51-2. Int J Cancer Suppl. 1992. PMID: 1428404 Review.

4

In vivo localization of a bispecific antibody which targets human T lymphocytes to lyse human colon cancer cells.

Barr IG, Miescher S, von Fliedner V, Buchegger F, Barras C, Lanzavecchia A, Mach JP, Carrel S. Barr IG, et al. Among authors: lanzavecchia a. Int J Cancer. 1989 Mar 15;43(3):501-7. doi: 10.1002/ijc.2910430327. Int J Cancer. 1989. PMID: 2647641

5

Human ovarian carcinoma lysis by cytotoxic T cells targeted by bispecific monoclonal antibodies: analysis of the antibody components.

Mezzanzanica D, Canevari S, Ménard S, Pupa SM, Tagliabue E, Lanzavecchia A, Colnaghi MI. Mezzanzanica D, et al. Among authors: lanzavecchia a. Int J Cancer. 1988 Apr 15;41(4):609-15. doi: 10.1002/ijc.2910410422. Int J Cancer. 1988. PMID: 3258590

6

Activation of mononuclear cells to be used for hybrid monoclonal antibody-induced lysis of human ovarian carcinoma cells.

Pupa SM, Canevari S, Fontanelli R, Ménard S, Mezzanzanica D, Lanzavecchia A, Colnaghi MI. Pupa SM, et al. Among authors: lanzavecchia a. Int J Cancer. 1988 Sep 15;42(3):455-9. doi: 10.1002/ijc.2910420324. Int J Cancer. 1988. PMID: 2971021

7

T-helper- and accessory-cell-independent cytotoxic responses to human tumor cells transfected with a B7 retroviral vector.

Döhring C, Angman L, Spagnoli G, Lanzavecchia A. Döhring C, et al. Among authors: lanzavecchia a. Int J Cancer. 1994 Jun 1;57(5):754-9. doi: 10.1002/ijc.2910570524. Int J Cancer. 1994. PMID: 7515023

8

A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation.

Maio M, Lahn M, Di Giacomo AM, Covre A, Calabrò L, Ibrahim R, Fox B; Siena Think Tank. Maio M, et al. J Exp Clin Cancer Res. 2021 Jul 23;40(1):240. doi: 10.1186/s13046-021-02023-4. J Exp Clin Cancer Res. 2021. PMID: 34301276 Free PMC article.

9

Triggering T cells by otherwise inert hybrid anti-CD3/antitumor antibodies requires encounter with the specific target cell.

Roosnek E, Lanzavecchia A. Roosnek E, et al. Among authors: lanzavecchia a. J Exp Med. 1989 Jul 1;170(1):297-302. doi: 10.1084/jem.170.1.297. J Exp Med. 1989. PMID: 2526194 Free PMC article.

10

Soluble CD40 ligand can replace the normal T cell-derived CD40 ligand signal to B cells in T cell-dependent activation.

Lane P, Brocker T, Hubele S, Padovan E, Lanzavecchia A, McConnell F. Lane P, et al. Among authors: lanzavecchia a. J Exp Med. 1993 Apr 1;177(4):1209-13. doi: 10.1084/jem.177.4.1209. J Exp Med. 1993. PMID: 7681469 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

397 results

Search Page

Filters